Engineering Antibodies Track Banner


抗体のエンジニアリング

このカンファレンスプログラムでは、抗体エンジニアリングの分野に従事している研究者や技術者がケーススタディや未発表の研究成果を披露する予定であり、次世代抗体工学についての着想を得ることができます。

Final Agenda

Recommended Short Course*

SC5: The Multi-Attribute Method (MAM) for Improving Product and Process Development

*Separate registration required

11月15日 (水)

07:45 Registration and Morning Coffee

08:30 Chairperson's Remarks

Jonas Schaefer, Ph.D., Head, High-Throughput Binder Selection Facility, Biochemistry, University of Zurich

08:35 KEYNOTE PRESENTATION: The Human Protein Atlas and Next Generation Antibody Therapeutics

Mathias_UhlenMathias Uhlen, Ph.D., Professor, Science for Life Laboratory, KTH Royal Institute of Technology

We have classified all the protein coding genes in humans using a combination of genomics, transcriptomics, proteomics and antibody-based profiling and used this data to study the global protein expression patterns in human cells, tissues and organs. A Tissue Atlas was launch in 2015, a Cell Atlas in 2016 and a Pathology Atlas will be launched in 2017. This open access knowledge-base can be used to explore targets for next generation antibody therapeutics.

治療薬としての新規抗体と抗体サブタイプ

09:05 IgA as Novel Isotype to Treat Cancer

Jeanette_LeusenJeanette Leusen, Ph.D., Associate Professor, Laboratory for Translational Immunology, University Medical Hospital Utrecht

· IgA employs different effector mechanisms compared to IgG

· IgA both for solid and hematological tumors in preclinical models

· Half-life enhancement by glycoengineering and FcRn targeting

09:35 Alphabodies: A Novel Class of Biologicals Acting on Intracellular Targets

Yvonne_McGrathYvonne McGrath, Ph.D., CSO, Complix NV

Many attractive intracellular targets involved in disease remain beyond the reach of conventional small molecules. We will describe the development of Alphabodies, a novel class of biologics that has been designed to enter cells effectively and interfere with key intracellular pathways. Data showing target binding, functional interference and results from animal models will be exemplified.

10:05 An Integrated Approach to Managing Immunogenicity Risk and Drug Immune Modulation

Jeremy Fry, D.Phil., Director, Sales, ProImmune

Immunogenicity is one of the most complex issues to address in drug design and development. Using case studies to illustrate, I will provide a comprehensive overview of the most appropriate tools to mitigate immunogenicity risk, including Mass Spectrometry antigen presentation assays; DC-T and T cell proliferation assays for biologic lead selection/optimization; HLA-peptide binding assays to characterize individual epitopes as well as undiluted whole blood cytokine storm assays.

10:35 Coffee Break in the Exhibit Hall with Poster Viewing

腫瘍以外の疾病への応用

11:15 Recombinant Antibody Brain Shuttles - Improved Immunotherapy and Diagnostics of Neurodegenerative Diseases

Greta_HultqvistGreta Hultqvist, Ph.D., Assistant Professor, Pharmaceutical Biosciences, Uppsala University

The blood brain barrier (BBB) hinders large molecules like antibodies to enter the brain and hence impedes immunotherapy and diagnostics of brain diseases. We have developed a symmetric BBB shuttle that transports antibodies across the BBB. It increases the uptake at diagnostic doses almost 100 times and at therapeutic 10 times. We have used this shuttle with an antibody that binds to the amyloid fibrils in Alzheimer's disease, and evaluated its performance as a therapeutic and diagnostic marker.

11:45 A Bispecific Antibody Mimetic of FGF21 for the Treatment of Type 2 Diabetes

James_ErnstJames A. Ernst, Ph.D., Senior Scientist, Protein Science, Genentech, Inc.

This talk will describe the discovery of an antibody that binds Klotho-Beta and FGFR1, thereby stimulating the cognate FGF21 co-receptor complex in adipose tissues. The selection of the receptor targeting arms will be described, and a mechanism of activation of this receptor-complex is proposed. In addition, a catabolic mechanism of FGF21 inactivation in serum by the Fibroblast Activation protein will be described and implications of this inactivation for recombinant and endogenous FGF21 discussed.

12:15 The Engineering of a HIV-1 Vaccine

Fernando_GarcesFernando Garces, Ph.D., Scientist, Molecular Engineering, Therapeutic Discovery, Amgen

Previous data has suggested that the Env protein is the most immunogenic when in its pre-fusion state making it paramount to favor this conformation in the designing of a vaccine capable of triggering a broad and potent immune response. Here we present the first high-resolution crystal structures of this viral spike in complex with anti-HIV antibodies and how this molecular information provides a rational platform for intensive engineering. The immunogenic properties of these native like trimer are currently being tested in a variety of animal models with promising results.

12:45 Design and Evaluation of Next-Generation Biologics for Cancer Immunotherapy

Maria Wendt, Ph.D., Head of Science Biologics, Genedata

Bi- and multi-specific antibodies, Ab-cytokine fusion proteins, non-Ig scaffolds, chimeric antigen receptors (CARs), engineered TCRs and TCR-based bispecific constructs can provide significant advantages for use in cancer immunotherapy. However, as highly engineered molecules they pose new design, engineering, cloning, expression, purification, and analytics challenges. Genedata Biologics enables the automated design, screening, production, and testing of large panels of these candidate therapeutic molecules and includes built-in tools for developability and manufacturability assessments.

13:15 Luncheon Presentation: Predicting and Managing Unwanted Immune Responses to Biologics

Mark Fogg, Ph.D., Group Leader, Immunology, Abzena

Understanding how therapeutic antibodies and proteins can induce an immune response in patients leading to the development of anti-drug antibodies (ADAs) Accurate and sensitive ways to assess the potential immunogenicity of proteins and antibodies ex vivo by measuring CD4+ T cell responses Methods for managing and reducing potential immunogenicity.



13:45 Session Break

抗体のプロファイリングとスクリーニング

14:00 Chairperson's Remarks

Jeanette Leusen, Ph.D., Associate Professor, Laboratory for Translational Immunology, University Medical Hospital Utrecht

14:05 Unique Properties of Mouse IgG

Joanna Bereta, Ph.D., Associate Professor, Cell Biochemistry, Faculty of Biochemistry, Biophysics and Biotechnology, The Jagiellonian University in Krakow

Contrary to the current belief that only IgMs are able to agglutinate erythrocytes, we obtained agglutinating mouse IgG3 that recognized antigen B of the human ABO blood group system. The high stability and production efficacy of IgG3 point to this molecule as a potent diagnostic tool. Mouse IgG3s efficiently neutralize pathogens with a polysaccharide envelope or carbohydrate-rich cell wall. However, the receptor specific for IgG3, which could participate in IgG3-based pathogen elimination, remains undiscovered; the results of our search for this high-affinity receptor will be presented.

14:35 A Systematic Approach for Peptide Characterization of B-Cell Receptor in Chronic Lymphocytic Leukemia

Manuel_FuentesManuel Fuentes, Ph.D., Scientist, Medicine & Proteomics Unit, Cancer Research Center, University of Salamanca

The profiling of Ig sequences (at both DNA and peptide levels) are of great relevance to developing targeted vaccines or treatments for specific diseases or infections. Thus, genomics and proteomics techniques (such as Next-Generation Sequencing (NGS) and mass spectrometry (MS)) have notably increased the knowledge in Ig sequencing and serum Ig peptide profiling in a high-throughput manner. Herein, it is described an integrated approach for genomics and proteomics data to sequence membrane-bound Ig presented in antigen specific B-cells.

15:05 HERA: A Human Endothelial Recycling Assay for Rapid Screening of FcRn-Mediated Rescue from Degradation

JanTerje_AndersenJan Terje Andersen, Ph.D., Associate Professor & Group Leader, Immunology, Centre for Immune Regulation, Department of Biosciences, Oslo University Hospital and University of Oslo

IgG and albumin have a remarkably long serum half-life of three weeks in humans, which is mainly due to an efficient FcRn-mediated pH-dependent recycling pathway. As these ligands are increasingly utilized as therapeutics, there is an intense interest in engineering of their half-life. Here, I will discuss a novel in vitro human endothelial cell-based rescue assay (HERA) that can easily be used for preclinical screening of FcRn-mediated rescue of engineered ligands.

15:35 Refreshment Break in the Exhibit Hall with Poster Viewing

創薬と改変のための哺乳類ディスプレイプラットフォーム

16:15 A Mammalian Display Platform for Antibody Discovery and Engineering Using Immunogenomic Engineering

Sai_ReddySai Reddy, Ph.D., Assistant Professor, Biosystems Science and Engineering, ETH Zurich

In this presentation, I will show how we combine NGS-based analysis with a novel mammalian hybridoma display platform for antibody screening and discovery. Specifically, we use NGS to identify candidate antigen specific clones from immunized repertoires. We then integrate these antibody clonal libraries into our hybridoma platform using CRISPR-Cas9 genome editing. Flow cytometry is then used to screen and isolate antigen-specific antibodies.

16:45 Mammalian Display for B- and T-Cell Receptor Discovery and Engineering

Marc_vanDijkMarc van Dijk, Ph.D., Executive Director, Platform Technology, Agenus

Agenus has invented novel display technologies to discover and engineer BCRs and TCRs, and will showcase their development of lab assays and bioinformatics algorithms to determine TCR specificity and off target liabilities.

17:15 Problem-Solving Breakout Discussions

18:15 Networking Reception in the Exhibit Hall with Poster Viewing

19:15 End of Day

11月16日 (木)

08:00 Registration and Morning Coffee

抗体選択とハイスループットスクリーニングのための技術

08:30 Chairperson's Remarks

Marc van Dijk, Ph.D., Executive Director, Platform Technology, Agenus

08:35 Application of Deep Mutational Scanning in Therapeutic Antibody Engineering

Patrick_KoenigPatrick Koenig, Ph.D., Senior Scientist, Antibody Discovery, AbbVie Stemcentrx

Deep mutational scanning combines the selection of limited mutagenesis libraries with deep sequencing. Here, I will present how information on sequence-function relationships obtained by deep mutational scanning is a powerful resource to guide the engineering of affinity, specificity and stability of potential therapeutic antibodies.

09:05 Efficient Mining of the Memory B Cell & Plasma Cell Repertoire - Next Generation Antibody Discovery

Dale Starkie, Research Scientist, Antibody Discovery, UCB Celltech

Here we describe the use of a number of cutting-edge antibody discovery technologies and assays to efficiently interrogate the memory B cell and the plasma cell repertoire of immunised animals and humans to identify rare antibodies with desirable functional characteristics. At the heart of this platform lies single cell isolation strategies which include both micromanipulation methods and droplet microfluidics. We will present case studies to demonstrate how we have applied them to discovery of antibodies against therapeutically-relevant targets.

09:35 MemoMAB: Gateway to Human Antibody Repertoires

Christoph_EsslingerChristoph Esslinger, Ph.D., CSO, Memo Therapeutics AG

The human immune repertoire is expected to yield valuable insights into novel protective mechanisms active in infectious diseases, cancer and other diseases. The MemoMAB microfluidics-based HT-single cell platform banks and displays authentic antibody repertoires from human donors in recombinant form making them directly accessible for immune repertoire analysis and antibody discovery using functional screening. MemoMAB processes up to 1mio B cells and directly delivers clonal cell lines expressing recombinant human antibodies.

10:05 Presentation to be Announced



10:35 Coffee Break in the Exhibit Hall with Poster Viewing

11:15 Technological Developments for Improved High-Throughput Binder Screenings and Validations

Jonas_SchaeferJonas Schaefer, Ph.D., Head, High-Throughput Binder Selection Facility, Biochemistry, University of Zurich

While recombinant binder selection pipelines by now work in rather high-throughput, the screening of suitable affinity reagents and especially the validation of their essential features for the final applications is still laborious and time-intensive. To optimize the efficiency of these processes, we have improved already existing and developed novel methods, combining chip-, SPR- and MS-technologies, to efficiently test candidates e.g. for crossreactivity and specificity.

11:45 Droplet Microfluidics for High Throughput Antibody and Vaccine Screening

Christoph_MertenChristoph Merten, Ph.D., Group Leader, Microfluidics, Genome Biology Unit, European Molecular Biology Laboratory (EMBL)

We have developed droplet-based microfluidic platforms that allow the direct screening of >1 million primary, non-immortalized plasma cells (optionally from humans) in a single experiment and also facilitate assays for the effect of antibodies on target cells (e.g. modulating GPCRs). In a complementary approach, we use the technology to monitor the binding of neutralizing antibodies to single HIV particles, which allows us to derive vaccine candidates with customized antigen properties (e.g. improved stability and accessibility).

 Twist Bioscience12:15 Luncheon Presentation to be Announced

13:00 Dessert Break in the Exhibit Hall with Poster Viewing

13:30 End of Engineering Antibodies

* 不測の事態により、事前の予告なしにプログラムが変更される場合があります。

Choose your language
Traditional Chinese
Simplified Chinese
Korean
English



カタログダウンロード
カタログ(PDF)


Premier Sponsor

Albumedix


スポンサー

 

Download CAG

 



メール配信サービス

関連イベント
PepTalk: The Protein Science Week 2018
14th Annual PEGS Boston